🧂New @freelyfiltered.bsky.social episode on hyponatremia correction #NephJC 🍾How can Brussels champagne help with hypoNa? 🎙️ Special invites: Ewot Hoorn @bettercallseeth.bsky.social 🎙️Filtrate: @kidneyboy.bsky.social @hswapnil.medsky.social @nephcrit.bsky.social www.nephjc.com/freelyfilter...

🩳New short from Dr. Sumaiya Ahmed and @hswapnil.medsky.social #NephSky 🔮Can we use prediction models to determine who might benefit from steroids in IgAN before immunosuppression initiation? www.nephjc.com/news/2026/7/1/can-we-predict-who-benefits-from-steroids-in-igan-the-pred-igan-study

🦵Had our Kick-off meeting today to welcome a new class of #NephJC interns (year 12 and counting). 👁️Keep an eye out for new blog and VA creators. See if you can Catch'em All🎣 #NephSky #MedSky @hswapnil.medsky.social @kidneyboy.bsky.social @nephroseeker.medsky.social @dramiliflores.bsky.social

1/10 With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage Could deeper B-cell depletion finally claim the throne? 👑 Read the article 👇 pubmed.ncbi.nlm.nih.gov/42246654/ #NephJC #TenPostNephJC #NephSky

The MAJESTRY trial, OBI vs TAC in membranous nephropathy. 👑 Visual abstract by Dr. Divya Bajpai #NephSky #NephJC www.nephjc.com/news/majestytrial

El resumen visual: MAJESTRY trial 👑 @dramiliflores.bsky.social and Dr. Divya Bajpai www.nephjc.com/news/ensayomajesty #NephSky #NephJC

Is it time for a new leader in membranous nephropathy, or is it just a game of thrones 👑? This week we're discussing OBI vs TAC in the MAJESTRY trial from #ERA26 🏰🐑 #NephSky We welcome back from retirement @jamiekwillows.bsky.social with the summary ✍️ www.nephjc.com/news/2026/06/22-majestyobi

🚨New 🩳 by @nephroseeker.medsky.social eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes? #NephSky #MedSky #NephJC www.nephjc.com/news/2026/short/measuredgfr

#TenPostNephJC #NephSky #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @glombandit.bsky.social kidney-international.org/article/S008...

Esta vez, @dramiliflores.bsky.social estaba muy ocupada! VA en espanol #NephJC #NephSky #MedSky www.nephjc.com/news/2026/6/1/p9klc2s43l9rrgqifsxgenky9kj81t

Do you biopsy pts with diabetes? Are you looking for diabetic nephropathy or something else? Check out the blog by @dramiliflores.bsky.social and Dr. Priya John #NephSky #MedSky 📣Now with a "audio abstract" at the top, preview if you want to read more! www.nephjc.com/news/2026/6/1/kidneybiopsy-dkd

Visual abstract on uncovering non-diabetic-kidney disease in the diabetic patient by @dramiliflores.bsky.social #NephJ #NephSky #MedSky www.nephjc.com/news/2026/6/1/ndkd-the-visual-abstract

recording an episode of @freelyfiltered.bsky.social with some filtrates and special guest Carla Nester from U IOwa #NephJC

Announcing the #NephJC internship class

✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...

#NephJC #TenPostNephJC. #NephSky 1/10 Building on the landmark findings of the SBP Intervention Trial, this study shows that team-based HTN care can successfully translate intensive BP control into meaningful CV benefits for underserved, low-income communities. pubmed.ncbi.nlm.nih.gov/41950472/

#NephSky #MedSky SPRINT told us that lower BPs improve CV outcomes. Can we implementation better BP strategies in low-income communities to achieve these goals? Guidelines are great, but real-world sustainable plans are better. #IMPACTSBP www.nephjc.com/news/2026-impact-bp

Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve BP control and adherence in low‑income patients 🎨 #VisualAbstract by @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/5/...

In this edition, @nephroseeker.medsky.social breaks down the Bayesian voodoo behind removing evil humor www.nephjc.com/news/2026/sh... #EMIMCC #NephSky

🚨Another #NephJC short 🩳 FINE ONE: Finerenone in Type 1 Diabetes Fine, but does it cross the finish line? Blog by @nephromommy-akshu.bsky.social #NephSky #MedSky www.nephjc.com/news/2026/5/4/fineone

1/10 #NephJC #TenPost #NephSky In 2026 the only FDA approved 💊 for FSGS is sparsentan, an endothelin A/angiotensin II receptor inhibitor. Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰 Read the article 👇 www.pubmed.ncbi.nlm.nih.gov/41616795/

Do you struggle with FSGS? Are you a sparsentan fan but asking, what's next? TRPC6 inhibitors completed a phase 2 study! Are we closing in on a common pathway of FSGS pathology? Blog by @drsaivani.bsky.social & @sayalibthakare.bsky.social #NephSky #MedSky www.nephjc.com/news/trcpc6inhibition-fsgs

👂So, did you hear the one about avacopan and data manipulation? 🧮🧮🧮 @hswapnil.medsky.social has added onto our ADVOCATE summary with a "postscript" review of the controversies. #NephSky #MedSky www.nephjc.com/news/advocate?rq=avacopan

Gracias @dramiliflores.bsky.social, el resumen visual en espanol #NephSky #MedSky www.nephjc.com/news/2026/trpc6-spanish

💊FSGS precision medications started with AMKD (APOL-1) and inaxaplin. 💊This week we're discussing FSGS and what else is in the pipeline of therapeutics...TRPC6 inhibitors. #NephSky #MedSky Check out the VA by Dr. Divya Bajpai www.nephjc.com/news/2026/5/3/trpc6-inhibition-the-visual-abstract

⏰This opportunity has a GFR of zero after May 1st (11:59 pm EST)- NephJC's Editorial Internship is closing 😉 Last chance to apply #NephJC www.nephjc.com/news/nephjc-...

⏳ Deadline in a few days! Want to level up your science‑communication game? 👇👇Apply to the #NephJC Editorial Internship and help craft the conversations that move nephrology forward www.nephjc.com/news/nephjc-...

Still ordering hydralazine? 🤔 Beyond case reports, this large cohort compares hydralazine vs ACEi/ARB to estimate real-world vasculitis risk, will this 📉 bias & clarify the answer Read more 👇 pubmed.ncbi.nlm.nih.... #TenPostNephJC #NephJC #NephSky #MedSky

Hydralazine, a 1950s drug still used at the edges of modern care. Cheap? Available? Signal of benefit… shadowed by decades of immune toxicity signals 15 min to #TenPostNephJC #NephJC #NephSky #MedSky pubmed.ncbi.nlm.nih.gov/6786464/

Hydralazine is most classically associated with which serologic pattern in ANCA vasculitis? 25 min #TenPostNephJC #Nephsky #MedSky #NephJC A. High-titer PR3-ANCA B. High-titer MPO-ANCA C. ANCA− / anti-GBM+ D. anti-dsDNA antibodies

Check out the VA on hydralazine and population vasculitis risk by Dr. Divya Bajpai #NephSky www.nephjc.com/news/2026/4/hydralazine-anca-va

Do you prescribe hydralazine? Or, do you 🛑 it as soon as you see it? Hydralazine persists despite TID dosing & risks like... vasculitis 🔥 Are you asking Why-dralazine? ✅The blog by @dramiliflores.bsky.social @nephroseeker.medsky.social #NephSky www.nephjc.com/news/hydralazine-anca-vasculitis

#NephJC and @theisn.org Advancing Clinical Trials collab for #Nephtrials STEPS trial tests coordinated system-level intervention to improve preemptive kidney transplant 🗓️XSpce: April 10, 12pm EST ✍️Blog by @dramiliflores.bsky.social and @nephroseeker.medsky.social www.nephjc.com/news/steps-n...

0/10 Hey NephJC faithful, we are shaking it up. Given the 📉 attendance at live chats we’re changing to a summary 🧵& ❓ to answer, at your convenience. Still tag us #NephJC to get the discussion going! PS If we hear enough comments, we might bring chats back!😉

In jut 1 hour #NephJC is unveiling something new... #NephSky #MedSky

Hey #NephSky #MedSky 📣If you were planning on coming to the #NephJC chat on hyponatremia 4/7/26 at 9 pm...relax, we're trying something new (and it will be on Twitter and BlueSky)! www.nephjc.com/news/2026/4/7/regarding-the-situation-withsocial-media-in-general

📖Check out the latest @kireports.bsky.social community blog on slowing ADPKD from @thekidneywhisperer.bsky.social #NephSky #MedSky www.kireportscommunity.org/post/stoppin...

🧂Hyponatremia. We see it. We fix it. #NephJC But what if fixing the sodium… doesn’t fix the patient? The HIT trial challenges one of medicine’s most reflexive moves ✍️ By @brianrifkin.bsky.social www.nephjc.com/news/hyponat...

Do you have #FOMO from missing all the fun at #ISNWCN ? We've got you covered!! Check out the interview with @nephroseeker.medsky.social and @hswapnil.medsky.social discussing simultaneous publications at WCN in Yokohama, Japan #NephSky www.nephjc.com/news/conf-coverage

Hiponatremia el resumen visual, gracias @dramiliflores.bsky.social #NephSky #NephJC www.nephjc.com/news/2026/4/4/hiponatremia-el-resumen-visual

📉Low asymptomatic sodium in a hospitalized patient: Are you chill 🧊 or do you treat 🛠️ ? Next #NephJC 4/7/26, we're changing it up (let's see if anyone notices 👀) #NephSky VA by @brianrifkin.bsky.social www.nephjc.com/news/2026/4/4/hyponatremia-correction-the-visual-abstract

🚨 #NephJC short 🩳from @kidneyboy.bsky.social The PUSH trial! 😉Can a wink, a nudge & a push encourage kidney stone formers to drink more fluid to prevent recurrence 🪨? (Hint: have 💦 behavioral trials worked in CHF or PCKD?) #NephSky #MedSky www.nephjc.com/news/2026/4/2/nephjc-short-the-push-trial

Covering the world 🌐 @hswapnil.medsky.social @nephroseeker.medsky.social 🧑‍💻Reporting in from Yokohama, Japan #ISNWCN 🌸 📰Read all about the late breaking news #NephJC #NephSky www.nephjc.com/news/isnwcn-yokohama

The #ISNWCN has high trial impact clinical trials to celebrate latest and more successful results in our nephro world To celebrate the joy of getting together, and to #NephItForward, we officially opened up the #NephJC Editorial Internship application www.nephjc.com/news/nephjc-...

1/ Today’s #nephjc graduation was pure joy. Seeing mentors and interns from around the world come together reminded me why this community matters. ✨Thank you for making it extraordinary

1/10 Welcome to #TenPostNephJC Can we move beyond slowing CKD → to actually repairing the kidney? Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.

Up next, we are taking a break on 03/24/26. Don’t forget to play NephMadness! www. ajkdblog.org/2026/03/01/welcome-to-nephmadness-2026/ We will return in April with WCN late breaking news. #NephJC Good night!

This is Dr. Sai Vani. It has been an honor to be your host tonight. I think all of us are celebrating WKD on March 12 and advocating for the importance of preventing kidney diseases and protecting planet Mother Earth. Goodbye until next time!

I sincerely thank all my #NephJC 2025-2026 interns! This is our last discussion. They are #FOAMed heroes. We could not do what we do without them. ♥️

Please thank your #NephJC 2025-2026 interns! This is their last discussion. They are #FOAMed heroes. We could not do what we do without them. ♥️